A practical reference on REV-ERB: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-23 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
=== Adhesion molecules of the immune system === Springer began his research career in immunology by studying the molecular basis for cellular immunity using as an example the interaction of cytotoxic T lymphocytes with antigen-bearing target cells. None of the molecules involved in this interaction had yet been defined, including the long postulated antigen-specific T cell receptor. However, it was known that Mg2+ was required for immune cell-cell interactions, and that interaction between fibroblasts and the extracellular matrix was similarly Mg2+-dependent. Postulating that adhesion receptors were likely to be similar to antibodies and were unlikely to require magnesium, Springer hypothesized that other molecules must be required for antigen-specific interactions. He immunized animals with cytotoxic T lymphocytes and screened for monoclonal antibodies that blocked antigen-specific killing. Using this functional assay, his laboratory identified a set of lymphocyte function-associated (LFA) antigens required for cytotoxic T-cell-mediated killing and other T cell-dependent responses, including LFA-1 (CD11a/CD18), LFA-2 (CD2), and LFA-3 (CD58). Springer's group then identified ICAM-1 as a ligand for LFA-1, demonstrating that this interaction is required for efficient antigen recognition by cytotoxic T cells, and later discovered ICAM-2 (CD102) and ICAM-3 (CD50), which have two to five immunoglobulin (Ig)-like domains and comprise a subfamily of the Ig superfamily.
Gabe Logan Newell (born November 3, 1962), known by his nickname Gaben, is an American video game developer and businessman who is the co-founder and president of the video game company Valve. Newell was born in Aspen, Colorado, and grew up in Davis, California. He attended Harvard University in the early 1980s but dropped out to join Microsoft, where he helped create the first versions of the Windows operating system. He also led development on a port of the game Doom for Windows 95. In 1996, Newell and Mike Harrington left Microsoft to found Valve and fund the development of their first game, Half-Life (1998). After the success of Half-Life, Harrington sold his stake in Valve to Newell and left in 2000. Newell led development of Valve's digital distribution service, Steam, which launched in 2003 and controlled most of the market for downloaded PC games by 2011. Forbes estimated that Newell owned at least half of Valve as of 2025. He is also the owner of the marine research organization Inkfish, the neuroscience company Starfish Neuroscience, and the custom yacht manufacturer Oceanco. Newell has been estimated as one of the wealthiest people in the United States and the wealthiest person in the video games industry, with an estimated net worth of $11 billion as of 2025.
Natural proteins can be engineered, for example, by directed evolution, novel protein structures that match or improve on the functionality of existing proteins can be produced. One group generated a helix bundle that was capable of binding oxygen with similar properties as hemoglobin, yet did not bind carbon monoxide. A similar protein structure was generated to support a variety of oxidoreductase activities while another formed a structurally and sequentially novel ATPase. Another group generated a family of G-protein coupled receptors that could be activated by the inert small molecule clozapine N-oxide but insensitive to the native ligand, acetylcholine; these receptors are known as DREADDs. Novel functionalities or protein specificity can also be engineered using computational approaches. One study was able to use two different computational methods: a bioinformatics and molecular modeling method to mine sequence databases, and a computational enzyme design method to reprogram enzyme specificity. Both methods resulted in designed enzymes with greater than 100 fold specificity for production of longer chain alcohols from sugar. Another common investigation is expansion of the natural set of 20 amino acids. Excluding stop codons, 61 codons have been identified, but only 20 amino acids are coded generally in all organisms. Certain codons are engineered to code for alternative amino acids including: nonstandard amino acids such as O-methyl tyrosine; or exogenous amino acids such as 4-fluorophenylalanine.
Sources: en.wikipedia.org
Asim K. Duttaroy is an Indian-born American medical scientist who, since 2001, has worked as a Professor at the Faculty of Medicine, University of Oslo, Norway. He was born in Gopinagar (Gangnapur), Nadia district, West Bengal, India. Duttaroy is the author of over 535 research papers (h-index 69, i-10 index 242) and book chapters, has authored or edited several books, and holds several international patents. His research contributions have led to several industrial developments worldwide, such as Provexis. Duttaroy, while he worked as Professor (1990-2001) at the Rowett Research Institute at the University of Aberdeen, Scotland, United Kingdom, discovered that an extract from tomato had a positive effect in the prevention of blood platelet aggregation. Hyperactive platelets are important mediators of atherogenesis. In addition to their roles in thrombosis, antiplatelet drugs are not suitable for use where the risk of a cardiovascular event is relatively low. Therefore, it is essential to find alternative, safe antiplatelet inhibitors for the vulnerable population with hyperactive platelets in order to reduce the risk of cardiovascular disease. Potent antiplatelet factors were identified in water-soluble tomato extract (Fruitflow®), significantly inhibiting platelet aggregation. It became the first product in Europe to receive an approved health claim under Article 13(5) of the European Health Claims Regulation 1924/2006 and is now commercially available in over 75 countries.
There were almost 18.3 million connections to the Internet in June 2014. According to Bloomberg, in 2013 Romania ranked fifth in the world, and according to The Independent, it ranks number one in Europe at Internet speeds, with Timișoara ranked among the highest in the world.
The University of London was government controlled from its establishment as an examining board in 1836 to its reconstitution as a more traditional teaching university in 1900. It has been described as "what today would be called a quango", operating out of government premises, staffed by civil servants, and directly accountable to the Treasury for its expenditure. Until 2019, the governing documents of publicly funded universities could only be modified with permission from the Privy Council. For the majority of publicly funded universities in England, the Higher Education and Research Act 2017 replaced Privy Council oversight with public interest governance regulations from the Office for Students. However, Privy Council oversight continues for almost all English institutions that were in the university sector before 1992, and would continue even if they were to cease to be publicly funded, due to their constitutional form as civil corporations, statutory corporations, or as chartered corporations.
== Philosophical background == Traditional Chinese medicine includes a broad range of practices sharing common concepts that developed in China for more than 2,000 years, including various forms of herbal medicine, acupuncture, massage (tui na), exercise (qigong), and dietary therapy. It is primarily used as a complementary alternative medicine approach. Traditional practices are widely used in China and, in an adapted form, also in the West. Its philosophy is based on School of Yin Yang, which incorporates Five Phases theory and Yin–Yang theory, and elements of which were absorbed by Daoism. Philosophical texts influenced medical thought and practice, mostly by being grounded in the same theories of qi, yin-yang and wuxing and microcosm-macrocosm analogies.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.